VJOncology is committed to improving our service to you

ESMO 2019 | IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC

VJOncology is committed to improving our service to you

David Spigel

Here, David Spigel, MD, Sarah Cannon Research Institute, Nashville, TN, provides an interim OS analysis of the Phase III IMpower110 study (NCT02409342) of atezolizumab vs platinum-based chemotherapy as a first-line treatment in PD-L1–selected non-small cell lung cancer (NSCLC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter